Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain – an individual patient analysis

References

• Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147:478-91
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006;32:304-15
   PubMed Web of Science ®Google Scholar
• Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg 2000;90:933-7
   PubMed Web of Science ®Google Scholar
• Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132:289-300
   PubMed Web of Science ®Google Scholar
• Sloan P, Hamann S. Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manag 2006;2:295-304
   PubMedGoogle Scholar
• Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J 2006;6:200-10
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004;43:983-1013
   PubMed Web of Science ®Google Scholar
• Pan L, Xu J, Yu R, et al. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 2005;133:209-20
   PubMed Web of Science ®Google Scholar
• Pan YX, Xu J, Mahurter L, et al. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun 2003;301:1057-61
   PubMed Web of Science ®Google Scholar
• Hall S, Gallagher RM, Gracely E, et al. The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose. Pain Med 2003;4:125-34
   PubMed Web of Science ®Google Scholar
• Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer 1998;83:1244-50
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003;74:102-12
   PubMed Web of Science ®Google Scholar
• Guay DR. Use of oral oxymorphone in the elderly. Consult Pharm 2007;22:417-30
   PubMedGoogle Scholar
• Gear RW, Miaskowski C, Gordon NC, et al. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 1996;2:1248-50
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 1995;61:195-201
   PubMed Web of Science ®Google Scholar
• Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54
   PubMed Web of Science ®Google Scholar
• Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006;14:56-64
   PubMed Web of Science ®Google Scholar
• Grilo RM, Bertin P, Scotto di Fazano C, et al. Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine 2002;69:491-4
   PubMed Web of Science ®Google Scholar
• Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain 2009;25:797-807
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Derry S, Moore RA, et al. Enriched enrollment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008;135:217-20
   PubMed Web of Science ®Google Scholar
• Straube S, Derry S, McQuay HJ, et al. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol 2008;66:266-75
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21-8
   PubMed Web of Science ®Google Scholar
• Katz N, Rauck R, Ahdieh H, et al. A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28
   PubMed Web of Science ®Google Scholar
• Peniston JH, Gould E. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. Clin Ther 2009;31:347-59
   PubMed Web of Science ®Google Scholar
• OPANA® ER (oxymorphone hydrochloride extended-release tablets). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA, 2008
   Google Scholar
• OxyContin® (oxycodone HCl controlled-release tablets). Full Prescribing Information, Purdue Pharma L.P., Stamford, CT, 2007
   Google Scholar
• Nielsen CK, Ross FB, Shahrdad L, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132:289-300
   PubMed Web of Science ®Google Scholar
• Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72:95-7
   PubMed Web of Science ®Google Scholar
• Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J 2001;18:205-7
   PubMed Web of Science ®Google Scholar
• Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain?. Acad Emerg Med 1998;5:1086-90
   PubMed Web of Science ®Google Scholar